NCI Drug Dictionary
The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.
- anti-EGFR/c-Met bispecific antibody EMB-01
A human, Fabs-in-tandem immunoglobulin (FIT-Ig)-based, tetravalent, bispecific antibody targeting both the epidermal growth factor receptor EGFR and the hepatocyte growth factor receptor (HGFR; c-Mesenchymal-Epithelial Transition; cMet; c-Met), with potential antineoplastic activity. Upon administration, anti-EGFR/c-Met bispecific antibody EMB-01 simultaneously targets and binds to wild-type or certain mutant forms of both EGFR and c-Met expressed on cancer cells, thereby preventing receptor phosphorylation. This prevents the activation of both EGFR- and c-Met-mediated signaling pathways and results in the inhibition of tumor cell proliferation. EGFR and c-Met, both upregulated or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation. In EMB-01, the two antigen-binding fragments (Fabs) are fused directly in a crisscross orientation resulting in four active and independent antigen binding sites. Check for active clinical trials using this agent. (NCI Thesaurus)
Synonym: anti-cMET/EGFR bispecific antibody EMB-01
anti-EGFR/anti-c-Met bispecific antibody EMB-01
bispecific antibody EMB-01
Code name: EMB 01